El-Shafey E M, El-Nagar G F, Selim M F, El-Sorogy H A, Sabry A A
Department of Internal Medicine, Nephrology, Faculty of Medicine, Tanta University, Tanta, Egypt.
Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt.
Clin Exp Nephrol. 2008 Oct;12(5):370-375. doi: 10.1007/s10157-008-0065-2. Epub 2008 Jun 21.
The etiology of hemodialysis (HD)-induced hypotension and hypertension remains speculative. There is mounting evidence that endothelin-1 (ET-1) may play a vital role in these hemodynamic changes. We examined the possible role of intradialytic changes of ET-1 in the pathogenesis of hypotension and rebound hypertension during HD.
The present study included 45 patients with end-stage renal disease (ESRD) on regular HD. They were divided according to their hemodynamic status during HD into three groups (group I had stable intradialytic hemodynamics, group II had dialysis-induced hypotension, and group III had rebound hypertension during HD). In addition, 15 healthy volunteers were included as a control group. Pulse and blood pressure were monitored before, during (every half hour), and after HD session. ET-1 level was measured at the beginning, middle, and end of HD. ET-1 was measured in the control group for comparison.
Pre-dialysis levels of ET-1 were significantly higher in dialysis patients compared to the controls (P < 0.001); however, they were comparable in the three HD groups. The post-dialysis ET-1 level was not changed significantly in group I compared with predialysis values (14.49 +/- 2.04 vs. 14.33 +/- 2.23 pg/ml; P = NS), while the ET-1 concentration decreased significantly in group II and increased in group III in comparison to predialysis values (8.56 +/- 1.44 vs. 11.75 +/- 2.51; 16.39 +/- 3.12 vs. 11.93 +/- 2.11 pg/ml, respectively; P < 0.001).
Altered ET-1 levels may be involved in the pathogenesis of rebound hypertension and hypotension during HD.
血液透析(HD)所致低血压和高血压的病因仍不明确。越来越多的证据表明,内皮素-1(ET-1)可能在这些血流动力学变化中起关键作用。我们研究了HD期间ET-1的透析内变化在低血压和反弹性高血压发病机制中的可能作用。
本研究纳入45例接受规律HD的终末期肾病(ESRD)患者。根据HD期间的血流动力学状态将他们分为三组(I组透析内血流动力学稳定,II组为透析诱导性低血压,III组为HD期间反弹性高血压)。此外,纳入15名健康志愿者作为对照组。在HD治疗前、治疗期间(每半小时)和治疗后监测脉搏和血压。在HD开始、中间和结束时测量ET-1水平。在对照组中测量ET-1以作比较。
与对照组相比,透析患者透析前ET-1水平显著更高(P < 0.001);然而,三组HD患者之间ET-1水平相当。与透析前值相比,I组透析后ET-1水平无显著变化(14.49 ± 2.04 vs. 14.33 ± 2.23 pg/ml;P = 无显著性差异),而与透析前值相比,II组ET-1浓度显著降低,III组则升高(分别为8.56 ± 1.44 vs. 11.75 ± 2.51;16.39 ± 3.12 vs. 11.93 ± 2.11 pg/ml;P < 0.001)。
ET-1水平改变可能参与HD期间反弹性高血压和低血压的发病机制。